Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Oragenics Appoints Dr. William “Frank” Peacock As Chief Clinical Officer for Conducting Phase Ii Clinical Trial

PUBLIC · OGENMay 22, 2024•about 2 years ago

Position

Chief Clinical Officer

Company

Oragenics

Frank Peacock

TampaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Oragenics, Inc. has appointed Dr. William “Frank” Peacock as its Chief Clinical Officer to oversee the anticipated Phase II clinical trial for treating concussion in the Emergency Department (ED), with the drug candidate ONP-002.

Company Information

Company

Oragenics

Location

4902 Eisenhower Blvd. Suite 125

Tampa, Florida, United States

About

Oragenics, Inc. is a biopharmaceutical company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders. The company is dedicated to the development of drug candidates for the treatment of mild Traumatic Brain Injury (TBI) and other related neurological conditions.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Oragenics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months